These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 17595258

  • 1. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial.
    Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, Gunther DF, Liu C, Geffner ME, Thrailkill K, Huseman C, Zagar AJ, Quigley CA.
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3406-16. PubMed ID: 17595258
    [Abstract] [Full Text] [Related]

  • 2. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial.
    Blum WF, Crowe BJ, Quigley CA, Jung H, Cao D, Ross JL, Braun L, Rappold G, SHOX Study Group.
    J Clin Endocrinol Metab; 2007 Jan; 92(1):219-28. PubMed ID: 17047016
    [Abstract] [Full Text] [Related]

  • 3. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
    Bannink EM, van Doorn J, Stijnen T, Drop SL, de Muinck Keizer-Schrama SM.
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
    [Abstract] [Full Text] [Related]

  • 4. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
    Binder G, Baur F, Schweizer R, Ranke MB.
    J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
    [Abstract] [Full Text] [Related]

  • 5. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [Abstract] [Full Text] [Related]

  • 6. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Delemarre-van de Waal HA, Vulsma T, Wit JM, Rouwé CW, Reeser HM, Gosen JJ, Rongen-Westerlaken C, Drop SL.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4013-21. PubMed ID: 8923853
    [Abstract] [Full Text] [Related]

  • 7. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
    de Zegher F, Du Caju MV, Heinrichs C, Maes M, De Schepper J, Craen M, Vanweser K, Malvaux P, Rosenfeld RG.
    J Clin Endocrinol Metab; 1999 May; 84(5):1558-61. PubMed ID: 10323379
    [Abstract] [Full Text] [Related]

  • 8. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial.
    Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL.
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4607-12. PubMed ID: 10599727
    [Abstract] [Full Text] [Related]

  • 9. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens.
    van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwé CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL.
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1119-25. PubMed ID: 12629094
    [Abstract] [Full Text] [Related]

  • 10. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome.
    Blum WF, Cao D, Hesse V, Fricke-Otto S, Ross JL, Jones C, Quigley CA, Binder G.
    Horm Res; 2009 Mar; 71(3):167-72. PubMed ID: 19188742
    [Abstract] [Full Text] [Related]

  • 11. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height.
    Quigley CA, Crowe BJ, Anglin DG, Chipman JJ.
    J Clin Endocrinol Metab; 2002 May; 87(5):2033-41. PubMed ID: 11994337
    [Abstract] [Full Text] [Related]

  • 12. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study.
    Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG, American Norditropin Study Group.
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2480-6. PubMed ID: 17356043
    [Abstract] [Full Text] [Related]

  • 13. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial.
    Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A.
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3584-90. PubMed ID: 12915640
    [Abstract] [Full Text] [Related]

  • 14. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment.
    Fjellestad-Paulsen A, Simon D, Czernichow P.
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1234-9. PubMed ID: 15001616
    [Abstract] [Full Text] [Related]

  • 15. Analyses from a centre of short- and long-term growth in Turner's syndrome on standard growth hormone doses confirm growth prediction algorithms and show normal IGF-I levels.
    Ranke MB, Schweizer R, Martin DD, Ehehalt S, Schwarze CP, Serra F, Binder G.
    Horm Res Paediatr; 2012 Mar; 77(4):214-21. PubMed ID: 22433161
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome.
    Menke LA, Sas TC, de Muinck Keizer-Schrama SM, Zandwijken GR, de Ridder MA, Odink RJ, Jansen M, Delemarre-van de Waal HA, Stokvis-Brantsma WH, Waelkens JJ, Westerlaken C, Reeser HM, van Trotsenburg AS, Gevers EF, van Buuren S, Dejonckere PH, Hokken-Koelega AC, Otten BJ, Wit JM.
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1151-60. PubMed ID: 20061421
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
    Kamp GA, Mul D, Waelkens JJ, Jansen M, Delemarre-van de Waal HA, Verhoeven-Wind L, Frölich M, Oostdijk W, Wit JM.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
    [Abstract] [Full Text] [Related]

  • 18. GH treatment to final height produces similar height gains in patients with SHOX deficiency and Turner syndrome: results of a multicenter trial.
    Blum WF, Ross JL, Zimmermann AG, Quigley CA, Child CJ, Kalifa G, Deal C, Drop SL, Rappold G, Cutler GB.
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1383-92. PubMed ID: 23720786
    [Abstract] [Full Text] [Related]

  • 19. The correlation of the IGF-I, IGFBP-3, and ALS generation test to height velocity after 6 months of recombinant growth hormone therapy in girls with Turner syndrome.
    Collett-Solberg PF, Pessoa de Queiroz AN, Cardoso ME, Jusan RC, Vaisman M, Guimarães MM.
    Growth Horm IGF Res; 2006 Aug; 16(4):240-6. PubMed ID: 16908209
    [Abstract] [Full Text] [Related]

  • 20. Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study.
    Jung H, Land C, Nicolay C, De Schepper J, Blum WF, Schönau E.
    Eur J Endocrinol; 2009 Feb; 160(2):149-56. PubMed ID: 19039085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.